Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
BioArctic AB (publ)
BRCTFBioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden. Address: Warfvinges vag 35, Stockholm, Sweden, 112 51
Analytics
Zielpreis von Wall Street
3 920.34 SEKKGV
–Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen BRCTF
Dividenden-Analyse BRCTF
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
155 %Verlauf der Dividende BRCTF
Bewertung der Aktie BRCTF
Finanzen BRCTF
Ergebnisse | 2019 | Dynamik |